Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus CLARITIN REDITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus CLARITIN REDITABS.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES vs CLARITIN REDITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a peripheral H1-receptor antagonist that selectively inhibits histamine-mediated effects on H1 receptors, reducing allergic symptoms. It does not penetrate the blood-brain barrier significantly, minimizing sedation.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
Adults and children 12 years and older: 180 mg orally once daily or 60 mg orally twice daily.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–15 hours) in healthy adults. This supports once-daily dosing. Half-life may be prolonged in patients with renal impairment (up to 19 hours).
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Fexofenadine is primarily excreted unchanged in feces (approximately 80%) via biliary elimination, with minimal renal excretion (approximately 11%). It is not metabolized by the liver.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Category A/B
Category C
Antihistamine
Antihistamine